Tags

Type your tag names separated by a space and hit enter

Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An observational study.
Maturitas. 2016 Dec; 94:131-136.M

Abstract

OBJECTIVES

This study aimed to assess the effect of the Microablative Fractional CO2 Laser (CO2-laser) therapy on vaginal pathophysiology and the symptoms of the Genitourinary Syndrome of Menopause (GSM).

METHODS

Postmenopausal women with moderate to severe symptoms of GSM underwent three sessions of CO2-laser therapy at monthly intervals. Participants were evaluated at baseline and 4 weeks after the last treatment.

MAIN OUTCOME MEASURES

The primary outcomes were Vaginal Maturation Value (VMV) and Vaginal Health Index Score (VHIS). Secondary outcomes included symptoms of GSM, Female Sexual Function Index (FSFI), International Consultation on Incontinence Questionnaire of Female Urinary Tract Symptoms (ICIQ-FLUTS) and Urinary Incontinence Short Form (ICIQ-UI SF), Urogenital Distress Inventory (UDI-6) and King's Health Questionnaire (KHQ).

RESULTS

Fifty-three postmenopausal women completed this study. VMV, VHIS and FSFI increased significantly. Dyspareunia, dryness, burning, itching, dysuria, frequency, urgency, urgency incontinence, stress incontinence and scores on the ICIQ-FLUTS, ICIQ-UI SF, UDI-6 and KHQ decreased significantly. Factors predicting for which women the CO2-laser therapy was more effective were not identified.

CONCLUSION

This study suggests that intravaginal CO2-laser therapy for postmenopausal women with clinical signs and symptoms of GSM may be effective in improving both vaginal pathophysiology and reported symptoms.

Authors+Show Affiliations

Urogynecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Urogynecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Cytology Department, "Alexandra Hospital", Athens, Greece.Urogynecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Obstetrics and Gynecology Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Urogynecology Unit, Milan, Italy.Urogynecology Unit, 1st Department of Obstetrics and Gynecology, "Alexandra" Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: athanasio@otenet.gr.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

27823733

Citation

Pitsouni, Eleni, et al. "Microablative Fractional CO2-laser Therapy and the Genitourinary Syndrome of Menopause: an Observational Study." Maturitas, vol. 94, 2016, pp. 131-136.
Pitsouni E, Grigoriadis T, Tsiveleka A, et al. Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An observational study. Maturitas. 2016;94:131-136.
Pitsouni, E., Grigoriadis, T., Tsiveleka, A., Zacharakis, D., Salvatore, S., & Athanasiou, S. (2016). Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An observational study. Maturitas, 94, 131-136. https://doi.org/10.1016/j.maturitas.2016.09.012
Pitsouni E, et al. Microablative Fractional CO2-laser Therapy and the Genitourinary Syndrome of Menopause: an Observational Study. Maturitas. 2016;94:131-136. PubMed PMID: 27823733.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An observational study. AU - Pitsouni,Eleni, AU - Grigoriadis,Themos, AU - Tsiveleka,Angeliki, AU - Zacharakis,Dimitris, AU - Salvatore,Stefano, AU - Athanasiou,Stavros, Y1 - 2016/09/16/ PY - 2016/07/18/received PY - 2016/08/31/revised PY - 2016/09/14/accepted PY - 2016/11/9/entrez PY - 2016/11/9/pubmed PY - 2017/4/30/medline KW - Dyspareunia KW - Menopause KW - Sexual function KW - Urgency KW - Urinary incontinence KW - Vulvovaginal atrophy SP - 131 EP - 136 JF - Maturitas JO - Maturitas VL - 94 N2 - OBJECTIVES: This study aimed to assess the effect of the Microablative Fractional CO2 Laser (CO2-laser) therapy on vaginal pathophysiology and the symptoms of the Genitourinary Syndrome of Menopause (GSM). METHODS: Postmenopausal women with moderate to severe symptoms of GSM underwent three sessions of CO2-laser therapy at monthly intervals. Participants were evaluated at baseline and 4 weeks after the last treatment. MAIN OUTCOME MEASURES: The primary outcomes were Vaginal Maturation Value (VMV) and Vaginal Health Index Score (VHIS). Secondary outcomes included symptoms of GSM, Female Sexual Function Index (FSFI), International Consultation on Incontinence Questionnaire of Female Urinary Tract Symptoms (ICIQ-FLUTS) and Urinary Incontinence Short Form (ICIQ-UI SF), Urogenital Distress Inventory (UDI-6) and King's Health Questionnaire (KHQ). RESULTS: Fifty-three postmenopausal women completed this study. VMV, VHIS and FSFI increased significantly. Dyspareunia, dryness, burning, itching, dysuria, frequency, urgency, urgency incontinence, stress incontinence and scores on the ICIQ-FLUTS, ICIQ-UI SF, UDI-6 and KHQ decreased significantly. Factors predicting for which women the CO2-laser therapy was more effective were not identified. CONCLUSION: This study suggests that intravaginal CO2-laser therapy for postmenopausal women with clinical signs and symptoms of GSM may be effective in improving both vaginal pathophysiology and reported symptoms. SN - 1873-4111 UR - https://www.unboundmedicine.com/medline/citation/27823733/Microablative_fractional_CO2_laser_therapy_and_the_genitourinary_syndrome_of_menopause:_An_observational_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5122(16)30232-8 DB - PRIME DP - Unbound Medicine ER -